All In Biotech

Drug Trial Radar · NCT03716024

Study the Efficacy and Safety of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

A Randomized, Evaluator-Blinded, Phase 2 Study to Compare the Safety and Efficacy of PTK 0796 With Linezolid (Zyvox®) in the Treatment of Adults With Complicated Skin and Skin Structure Infection (cSSSI)

Last checked: Nov 20, 2026Latest source record: Oct 12, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 234 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

234

Actual

Start

Jul 18, 2007

Primary completion

Jan 7, 2008

Study completion Jan 7, 2008

Sponsor

Lead sponsor
Paratek Pharmaceuticals IncIndustry
Sponsor type
Industry
First posted
Oct 23, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase II trial to demonstrate the safety and efficacy of PTK 0796 in the treatment of complicated skin and skin structure infections (cSSSI).

Conditions

  • Infectious Skin Disease
  • Bacterial Skin Disease

Interventions

  • PTK 0796Drug

    PTK 0796 100 mg for injection; PTK 0796 capsule 100 mg

  • LinezolidDrug

    Pre-mixed 600 mg IV infusion solution; Linezolid 600 mg tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Clinical Response in the Modified Intent-to-Treat (mITT) PopulationTime frame: 10 to 17 days after the last dose of test article (intravenous or oral) (total treatment of up to 14 days)
  2. Number of Participants With Clinical Response in the Clinically Evaluable (CE) PopulationTime frame: 10 to 17 days after the last dose of test article (intravenous or oral) (total treatment of up to 14 days)

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Paratek Recruiting Site

    Anaheim, California

  • Paratek Recruiting Site

    Buena Park, California

  • Paratek Recruiting Site

    Chula Vista, California

  • Paratek Recruiting Site

    Hawaiian Gardens, California

  • Paratek Recruiting Site

    Oceanside, California

  • Paratek Recruiting Site

    San Jose, California

  • Paratek Recruiting Site

    Indianapolis, Indiana

  • Paratek Recruiting Site

    Butte, Montana

  • Paratek Recruiting Site

    Electra, Texas

  • Paratek Recruiting Site

    Houston, Texas

  • Paratek Recruiting Site

    Wichita Falls, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.